Multiple Sclerosis (MS) is the most common inflammatory demyelinating diseases of the central nervous system (CNS) in young adults with a high risk of future disability. Although the search for antibodies in MS has led to controversial results, most recent data suggest that CNS-reactive B cells are present in patients with MS or related diseases.
Therefore, the young scientist Dr. Simone Mader from the Institute for Clinical Neuroimmunology at LMU in Munich wants to detect brain-reactive B cells in patients with MS and related diseases through usage of novel methodological approaches. This will allow her to identify autoantibodies and their target antigens. The project has immense importance for the understanding, diagnosis and treatment of patients with MS and related disorders.
The project of Simone Mader is supported by the “Young Investigator Fund for Innovative Research Ideas” of the Schering Stiftung and the Fritz Thyssen Foundation.Share this post
Dr. Simone Mader obtained her PhD in Neuroscience at the Medical University of Innsbruck, Austria. In 2012 she continued her research as a postdoc in the lab of Dr. Betty Diamond at the Feinstein Institute for Medical Research in New York. She received a postdoctoral fellowship from the S.L.E. Lupus Foundation and was promoted to instructor in 2017. Since her return to Europe in June 2018, she has been working at the Ludwig-Maximilians-Universität München in the group of Prof. Dr. Edgar Meinl at the Institute of Clinical Neuroimmunology.
Unter den Linden 32-34
Telefon: +49 - 30 - 20 62 29 65
Thursday to Monday: 1 pm - 7 pm